Dear Healthcare Professional,

At MPR, we strive to bring you important drug information in a concise and timely manner. In keeping with this goal, we are pleased to provide you with this PRESCRIBING ALERT about QVAR® (beclomethasone dipropionate HFA) Inhalation Aerosol, a product of Teva Respiratory, LLC. QVAR now has a built-in dose counter that helps patients keep track of their remaining doses and know when it is time to refill their prescription. This PRESCRIBING ALERT highlights helpful features, guideline recommendations, and health plan coverage for QVAR.

Indication
QVAR® (beclomethasone dipropionate HFA) Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. QVAR is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR may reduce or eliminate the need for systemic corticosteroids.

Important Safety Information
• QVAR is not a bronchodilator and is not indicated for relief of acute bronchospasm

CAUTION: Adrenal insufficiency may occur when transferring patients from systemic steroids (see WARNINGS, Prescribing Information).
• A reduction in growth velocity in growing children and teenagers may occur as a result of inadequate control of chronic diseases such as asthma or from use of corticosteroids for treatment
• Common side effects associated with the use of QVAR and placebo in clinical trials include, but are not limited to, headache (12% and 9%, respectively) and pharyngitis (8% and 4%, respectively)

Please see full Prescribing Information for QVAR.

More information about QVAR is available in the current edition of MPR.

Sincerely,

Dimpy Mehra, PharmD
Clinical Communications Specialist
MPR Custom Programs

REFERENCE
1. QVAR [prescribing information]. Horsham, PA: Teva Respiratory, LLC; May 2014.

QVA-40664 09/14
QVAR®
(beclomethasone dipropionate HFA)
Inhalation Aerosol

Company: Teva Pharmaceuticals
Pharmacologic class: Steroid
Active Ingredient: Beclomethasone dipropionate 40 mcg/inhalation, 80 mcg/inhalation metered-dose inhaler.
Indication: Maintenance treatment of asthma as prophylactic therapy in patients 5 years of age or older. Asthma requiring systemic corticosteroid therapy, to reduce or eliminate need for systemic corticosteroids.

Adults: Previously on bronchodilators alone: initially 40–80 mcg twice daily; max 320 mcg twice daily. Previously on inhaled corticosteroids: initially 40–160 mcg twice daily; max 320 mcg twice daily.
Children: <5yrs: not recommended. 5–11yrs: initially 40 mcg twice daily; max 80 mcg twice daily.
How Supplied: Inhaler—8.7 g (120 inhalations)

☑️ QVAR® now has a dose counter to help patients keep track of remaining doses

☑️ QVAR® is the only asthma control inhaler with a built-in dose counter with numbers that turn red when it is time to refill

■ The dose counter is located on the back of the actuator, and shows the number of actuations of medicine remaining in units of 2
■ When the dose counter on the actuator reaches the number 20, the color of the numbers will change to red. This will remind patients to refill their prescription
■ When the dose counter reaches 0, the background color will change to solid red
■ The QVAR® inhaler should be thrown away as soon as the dose counter reads 0 or by the expiration date on the QVAR® inhaler package, whichever comes first

Important Safety Information
• QVAR® is not a bronchodilator and is not indicated for relief of acute bronchospasm

CAUTION: Adrenal insufficiency may occur when transferring patients from systemic steroids (see WARNINGS, Prescribing Information).

Please see Important Safety Information throughout and full Prescribing Information.

(continued on next page)
QVAR® is a small-particle inhaled corticosteroid that targets the chronic inflammation in both the large and small airways\(^6,7\)

Small airways are a vital therapeutic target for achieving asthma control\(^3\)

- Uncontrolled asthma has been associated with small airway dysfunction\(^4\)
- Small (distal) airways—those <2 mm in diameter—are significant sites of chronic inflammation\(^3,5\)
- Inflammation-related structural changes in the small (distal) airways may have a dramatic effect on the pathogenesis and treatment of the disease\(^3\)
- Chronic inflammation in small and large airways may be associated with\(^3\)
  - Asthma exacerbations
  - Progressive decline in lung function in adults
  - Airway remodeling

The majority of QVAR® (beclomethasone dipropionate HFA) Inhalation Aerosol was deposited in and distributed throughout the lung\(^8,9\)

- When tracked by scintigraphy, up to 68% of QVAR® was deposited in the lung\(^8,9\)
  - Scintigraphy is not a valid surrogate for clinical effect

**DISTRIBUTION OF QVAR® IN LUNGS**

<table>
<thead>
<tr>
<th>Lung Regions as Isolated for Imaging*</th>
<th>Distribution of QVAR® Deposited in the Lungs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central</td>
<td>31%</td>
</tr>
<tr>
<td>Intermediate</td>
<td>36%</td>
</tr>
<tr>
<td>Peripheral</td>
<td>33%</td>
</tr>
</tbody>
</table>

The relationship of lung deposition to clinical efficacy is unknown.

*Based on an open-label study in 7 patients with mild asthma designed to determine the lung deposition and distribution of radiolabeled HFA-BDP from 2 devices, using coordinated and discoordinated techniques in the P&B inhaler. The distribution shown here is for the P&B on-time group, who were trained to actuate 0.32 sec after start of inspiration.\(^10\)

HFA-BDP = hydrofluoroalkane-beclomethasone dipropionate; P&B = press and breathe.

Source: Leach 2005.\(^10\)

Important Safety Information (continued)

- A reduction in growth velocity in growing children and teenagers may occur as a result of inadequate control of chronic diseases such as asthma or from use of corticosteroids for treatment

Please see Important Safety Information throughout and full Prescribing Information.
QVAR® (beclomethasone dipropionate HFA) Inhalation Aerosol helps provide asthma control.

In a 1-year, observational, retrospective, matched-cohort analysis of the UK’s General Practice Research Database for 1319 patients 5 to 60 years of age receiving a first prescription or dose increase of QVAR®:

- 92% of patients initiated on QVAR® experienced no exacerbation. The mean daily dose of QVAR® in this study cohort was within the NAEPP-estimated low daily-dose range for youths ≥12 years of age and adults.

The National Asthma Education and Prevention Program (NAEPP) and the FDA list inhaled corticosteroid (ICS) monotherapy as a first-line treatment in patients with mild to moderate persistent asthma.

QVAR® has class-leading preferred health-plan coverage:

- At 93%, QVAR® has the most preferred formulary coverage among ICSs
- At 96%, QVAR® has the most covered lives among ICSs
- This could mean
  - Fewer pharmacy callbacks
  - Less hassle for office staff
  - Lower copays for insured patients

Important Safety Information (continued)

- Common side effects associated with the use of QVAR® and placebo in clinical trials include, but are not limited to, headache (12% and 9%, respectively) and pharyngitis (8% and 4%, respectively)

Please see Important Safety Information throughout and full Prescribing Information.

(continued on next page)
Indication
QVAR® (beclomethasone dipropionate HFA) Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. QVAR® is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR® may reduce or eliminate the need for the systemic corticosteroids.

Important Safety Information
• QVAR® is not a bronchodilator and is not indicated for relief of acute bronchospasm
CAUTION: Adrenal insufficiency may occur when transferring patients from systemic steroids (see WARNINGS, Prescribing Information).
• A reduction in growth velocity in growing children and teenagers may occur as a result of inadequate control of chronic diseases such as asthma or from use of corticosteroids for treatment
• Common side effects associated with the use of QVAR® and placebo in clinical trials include, but are not limited to, headache (12% and 9%, respectively) and pharyngitis (8% and 4%, respectively)

Please see full Prescribing Information

REFERENCES
1. QVAR [prescribing information]. Horsham, PA: Teva Respiratory, LLC; May 2014.

QVAR is a registered trademark of IVAX LLC, a member of the Teva Group.
©2014 Teva Respiratory, LLC
QVA-40664 09/14

This MPR Prescribing Alert is produced as a basic reminder of important information for healthcare professionals. Readers are advised to consult manufacturers and specialists if questions arise about specific products, treatments, or diseases. The publisher and editors do not assume liability for any errors or omissions. MPR and MPR Prescribing Alert are registered trademarks of Haymarket Media, Inc. © 2014 Haymarket Media, Inc.